Franco Leonel Marsico

Dr. Franco Leonel Marsico

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2021 in eClinicalMedicine
Verified
Journal Article
Open access
SGSoledad González
Soledad González
SOSantiago Olszevicki
Santiago Olszevicki
MSMartín Salazar
Martín Salazar
ACAna Calabria
Ana Calabria
LRLorena Regairaz
Lorena Regairaz
FMFranco Leonel Marsico
Franco Leonel Marsico
A first-dose of various vaccines provides acceptable protection against infections by SARS-CoV-2 and evolution to the most severe forms of COVID-19. The recombinant adenovirus (rAd)-based vaccine, Gam-COVID-Vac (Sputnik V), was proven efficacious but information about effectiveness in the real-world setting is lacking. The aim of our study was to investigate the association between the rollout of the first component (rAd26) of Gam-COVID-Vac and PCR-positive tests, hospitalisations and deaths. We conducted a retrospective cohort study which analyzed individuals aged 60-79 who self-registered in the online vaccination system of the Province of Buenos Aires, Argentina, from December 29, 2020 to March 21, 2021. Exclusion criteria were having a previous positive RT-PCR or antigen tests for SARS-CoV-2, having received other vaccines, or two doses of any vaccine. Proportions of new laboratory-confirmed SARS-CoV-2 infections, hospitalisations and deaths until 83 days of vaccination were compared between vaccinated and unvaccinated subjects. Vaccine effectiveness for the three outcomes was calculated as (1–OR) × 100. Kaplan-Meier cumulative incidence curves were constructed. During the study period 415995 registered subjects received the first component of Gam-COVID-Vac; 40387 belonged to the 60-79 age group, and were compared to 38978 unvaccinated. Vaccine effectiveness for preventing laboratory-confirmed infections was 78•6% [CI95% 74·8 - 81·7]; and for reducing hospitalizations and deaths was, respectively, 87·6% [CI95% 80·3 - 92·2] and 84·8% [CI95% 75·0 - 90·7]. Effectiveness was high across all subgroups. Similarly to other vaccines, the administration of one dose of Gam-COVID-Vac was effective for a wide range of COVID-19–related outcomes. This study did not receive any funding.

16 July 2022 in The Lancet Regional Health - Americas
Verified
Journal Article
Open access
SGSoledad González
Soledad González
SOSantiago Olszevicki
Santiago Olszevicki
AGAlejandra Gaiano
Alejandra Gaiano
ABAna Nina Varela Baino
Ana Nina Varela Baino
LRLorena Regairaz
Lorena Regairaz
FMFranco Leonel Marsico
Franco Leonel Marsico
Background Although paediatric clinical presentations of COVID-19 are usually less severe than in adults, serious illness and death have occurred. Many countries started the vaccination rollout of children in 2021; still, information about effectiveness in the real-world setting is scarce. The aim of our study was to evaluate vaccine effectiveness (VE) against COVID-19-associated-hospitalisations in the 3-17-year population during the Omicron outbreak. Methods We conducted a retrospective cohort study including individuals aged 3-17 registered in the online vaccination system of the Buenos Aires Province, Argentina. mRNA-1273 and BNT162b2 were administered to 12-17-year subjects; and BBIBP-CorV to 3-11-year subjects. Vaccinated group had received a two-dose scheme by 12/1/ 2021. Unvaccinated group did not receive any COVID-19 vaccine between 12/14/2021 and 3/9/2022, which was the entire monitoring period. Vaccine effectiveness (VE) against COVID-19-associated hospitalisations was calculated as (1-OR)x100. Findings By 12/1/2021, 1,536,435 individuals aged 3-17 who had received zero or two doses of SARS-CoV-2 vaccines were included in this study. Of the latter, 1,440,389 were vaccinated and 96,046 not vaccinated. VE were 78.0% [68.7- 84.2], 76.4%[62.9- 84.5] and 80.0%[64.3- 88.0] for the entire cohort, 3- 11-year (BBIBP-CorV) subgroup and 12- 17 (mRNA vaccines) subgroup, respectively. VE for the entire population was 82.7% during the period of Delta and Omicron overlapping circulation and decreased to 67.7% when Omicron was the only variant present. Interpretation This report provides evidence of high vaccine protection against associated hospitalisations in the paediatric population during the Omicron outbreak but suggests a decrease of protection when Omicron became predominant. Application of a booster dose in children aged 3-11-year warrants further consideration. Copyright (c) 2022 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

1 November 2020 in Forensic Science International: Genetics
Verified
Journal Article
Open access
MVMagnus Dehli Vigeland
Magnus Dehli Vigeland
FMFranco Leonel Marsico
Franco Leonel Marsico
MPMariana Herrera Piñero
Mariana Herrera Piñero
TEThore Egeland
Thore Egeland
Missing person identification typically involves genetic matching of a person of interest against relatives of the missing person. In cases with few available relatives, exhumations or other substantial efforts may be necessary in order to secure adequate statistical power. We propose a simulation approach for solving prioritisation problems arising in such cases. Conditioning on the already typed individuals we estimate the power of each alternative, both to detect the true person, and to exclude false candidates. Graphical summaries of the simulations are given in complementary power plots, facilitating interpretation and decision making. Through a series of examples originating from the well-known Missing grandchildren of Argentina we demonstrate that our method may untangle complex prioritisation problems and other power-related questions. In particular we offer novel insights in recent cases where only children of the potential match are available for testing. We also show that X-chromosomal markers may give high statistical power in missing person identification, but that this requires careful selection of relatives for genotyping. All simulations, power calculations and plots are done with the R package forrel.

27 January 2025 in Forensic Science International: Genetics
Verified
Journal Article
Closed access
FMFranco Leonel Marsico
Franco Leonel Marsico
MAMartin Amigo
Martin Amigo

28 September 2023 in The Lancet Regional Health - Americas
Verified
Journal Article
Open access
SGSoledad González
Soledad González
SOSantiago Olszevicki
Santiago Olszevicki
AGAlejandra Gaiano
Alejandra Gaiano
MSMartín Salazar
Martín Salazar
LRLorena Regairaz
Lorena Regairaz
FMFranco Leonel Marsico
Franco Leonel Marsico
After primary vaccination schemes with rAd26-rAd5 (Sputnik V), ChAdOx1 nCoV-19, BBIBP-CorV or heterologous combinations, the effectiveness of homologous or heterologous boosters (Sputnik V, ChAdOx, Pfizer-BioNTech, Moderna) against SARS-CoV-2 infections, hospitalisations and deaths has been scarcely studied. Test-negative, case–control study, conducted in Argentina during omicron BA.1 predominance, in adults ≥50 years old tested for SARS-CoV-2 who had received two or three doses of COVID-19 vaccines. Outcomes were COVID-associated infections, hospitalisations and deaths after administering mRNA and vectored boosters, < or ≥60 days from the last dose. Of 422,124 individuals tested for SARS-CoV-2, 221,993 (52.5%) tested positive; 190,884 (45.2%) and 231,260 (54.8%) had received 2-dose and 3-dose vaccination schemes, respectively. The 3-dose scheme reduced infections, hospitalisations and death (OR 0.81 [0.80–0.83]; 0.28 [0.25–0.32] and 0.25 [0.22–0.28] respectively), but protection dropped after 60 days to 1.04 [1.01–1.06]; 0.52 [0.44–0.61] and 0.38 [0.33–0.45]). Compared with 2-dose-schemes, homologous boosters after primary schemes with vectored-vaccines provided lower protection against infections < and ≥60 days (0.94 [0.92–0.97] and 1.05 [1.01–1.09], respectively) but protected against hospitalisations (0.30 [0.26–0.35]) and deaths (0.29 [0.25–0.33]), decreasing after 60 days (0.59 [0.47–0.74] and 0.51 [0.41–0.64], respectively). Heterologous boosters protected against infections (0.70 [0.68–0.71]) but decreased after 60 days (1.01 [0.98–1.04]) and against hospitalisations and deaths (0.26 [0.22–0.31] and 0.22 [0.18–0.25], respectively), which also decreased after 60 days (0.43 [0.35–0.53] and 0.33 [0.26–0.41], respectively). Heterologous boosters protected against infections when applied <60 days (0.70 [0.68–0.71], p < 0.001), against hospitalisations when applied ≥60 days (0.43 [0.35–0.53], p < 0.01), and against deaths < and ≥60 days (0.22 [0.18–0.25], p < 0.01 and 0.33 [0.26–0.41], p < 0.001). During omicron predominance, heterologous boosters such as viral vectored and mRNA vaccines, following Sputnik V, ChAdOx1, Sinopharm or heterologous primary schemes might provide better protection against death; this effect might last longer in individuals aged ≥50 than homologous boosters. None.

10 June 2023 in Forensic Science International: Genetics
Verified
Journal Article
Closed access
FMFranco Leonel Marsico
Franco Leonel Marsico
ICInés Caridi
Inés Caridi